P. P. Shao, F. Ye / Tetrahedron Letters 49 (2008) 3554–3557
3557
OH
F
F
F
F
g
c,d,e
a,b
f
CO2Me
CO2Me
86%
CON3
NHCBz
92%
NH2
3a -trans
3b -cis
2a -cis
2b -trans
9a -cis
9b -trans
10a -cis
10b -trans
1a -cis
1b -trans
Scheme 3. Reagents and conditions: (a) Tf2O, pyridine, CH2Cl2, ꢀ78 °C to 21 °C over 15 min; (b) TBAF 2 equiv, 21 °C, 15 min; (c) LiOH, MeOH, H2O,
50 °C, 2 h; (d) DIEA, Ethylchloroformate, acetone, 0 °C, 30 min; (e) NaN3, 21 °C, 30 min; (f) BnOH, toluene, 110 °C, 16 h; (g) Pd/C, H2 50 psi, EtOH,
4 h.
4. Corbel, B.; Durst, T. J. Org. Chem. 1976, 41, 2348.
5. Jeffery, J. E.; Kerrigan, F.; Miller, T. K.; Smith, G.; Tometzki, G. B.
of the fluorinated product with complete inversion of
stereochemistry.
J. Chem. Soc., Perkin Trans. 1 1996, 2583.
With pure 2a and 2b in hand, the final conversion of the
6. Complete
cis-selective cyclization with phenylacetic acid and
ester to the corresponding amine was accomplished. The
hydrolysis of esters 2a and 2b, and the subsequent addition
of sodium azide to the activated carboxylates afforded the
corresponding acyl azides 9a and 9b. These were converted
to the benzyl carbamate-protected amines 10a and 10b by
Curtius rearrangement of the acyl azides followed by trap-
ping of the isocyanate intermediates with benzyl alcohol
(40% yield over 4 steps). Finally, removal of the CBz group
by hydrogenolysis was straightforward, affording 1a and 1b
in 24% and 19% overall yield, respectively, from common
starting materials.13
In summary, we report the first stereoselective synthesis
of cis- and trans-3-fluoro-1-phenylcyclobutyl amines 1a
and 1b. Excellent selectivity for both cis- and trans-isomers
has been achieved from the reduction of ketoacid 4 with L-
Selectride or from ketoester 5 with NaBH4, respectively.
epibromohydrin has been achieved. Personal communication with
Dr. Jinjun Yin.
7. (a) Manatt, S. L.; Vogel, M.; Knutson, D.; Roberts, J. D. J. Am.
Chem. Soc. 1964, 86, 2645; (b) Langley, C. H.; Lii, J.-H.; Allinger, N.
L. J. Comput. Chem. 2001, 22, 1451.
8. Pigou, P. E.; Schiesser, C. H. J. Org. Chem. 1988, 53, 3841.
9. Korb, G.; Flemming, H.; Lehnert, R.; Rybczynski, W. WO200018715.
10. Cis- and trans-isomers were assigned based on NOE effects, and the
ratio was determined by 1H NMR integration of H1 and H2 of the cis-
and trans-isomers.
3.8%
CN
H3
CN
OH
H3
H4
H4
OH
H2
H1
H2
H1
2.9%
3.1%
3%
.
11. The preferred conformations of 3-Ph-3-R-substituted cyclobutanones
(4, 7, 5, and 8) were calculated using two molecular mechanics
methods, MMFFs and OPLS-2005, in simulated high-dielectric
solvent. However, the two methods yielded conflicting results.
MMFFs calculation showed conformation I is the preferred confor-
mation (pucker angle h for 4, 7, 5, and 8: 29.2°, 22.6°, 29°, and 29.4°)
while OPLS calculation indicated conformation III being preferred
(pucker angle h for 4, 7, 5, and 8:23°, 21.4°, 23.2°, and 22.8°). Density
Acknowledgments
We thank Professor Robert Boeckman for useful discus-
sions on the mechanism of stereoselectivity in cyclobuta-
none reduction, Dr. Jinjun Yin for sharing unpublished
results, and Dr. Daniel McMasters for performing the
molecular mechanics and ab initio calculations. We also
thank Ms. Deborah Pan and Dr. Joseph L. Duffy for
proof-reading the manuscript.
*
functional theory (DFT) calculations (B3LYP/6-31G ) indicated that
the cyclobutanone is nearly planar (conformation II with pucker
angle h for 4, 7, 5, and 8: 8.4°, 8.8°, 8.6°, and 9.4°).
12. (a) Middleton, W. J. J. Org. Chem. 1975, 40, 574; (b) Avent, A. G.;
Bowler, A. N.; Doyle, P. M.; Marchand, C. M.; Young, D. W.
Tetrahedron Lett. 1992, 33, 1509; (c) Demange, L.; Menez, A.;
Dugave, C. Tetrahedron Lett. 1998, 39, 1169.
References and notes
13. Compound 1a: 1H NMR (500 MHz, CDCl3): d (ppm) 7.46 (d,
3
3
0
0
JH–H = 7.4 Hz, 2H), 7.40 (t,
JH–H = 7.6 Hz, 2H), 7.30 (t,
1. (a) Filler, R. Organofluorine Compounds in Medicinal Chemistry and
Biomedical Applications. In Studies in Organic Chemistry 48; Filler,
R., Ed.; Elsevier: New York, 1993; pp 1–386; (b) Fluorine in
Bioorganic chemistry; Welch, J. T., Eswarakrishnan, S., Eds.; Wiley:
New York, 1991; pp 1–261; (c) Lin, P.; Jing, J. Tetrahedron 2000, 56,
3635.
2. McAtee, J. J.; Schinazi, R. F.; Liotta, D. C. J. Org. Chem. 1998, 63,
2161 and references cited therein.
3. (a) Silverman, R. B.; Zieske, P. A. Biochemistry 1996, 25, 341; (b) Cui,
Yi; Tinker, A.; Clapp, L. H. Br. J. Pharmcol. 2003, 139, 122; (c)
Ohnari, M.; Nishio, K.; Sakurai, K. WO2001068671.
3
2
0
JH–H = 7.4 Hz, 1H), 4.88 (dm, JH–F = 62.7 Hz, 1H), 3.1 (m, 2H),
2.5 (m, 2H); 13C NMR (CDCl3): d (ppm) 146.5, 128.9, 127.3, 125.8,
1
3
82.3 (d, JC–F = 205.4 Hz), 52.1 (d, JC–F = 17.3 Hz), 46.8 (d,
2JC–F = 19.2 Hz); 19F NMR (CDCl3): d (ppm) ꢀ65.8. Compound
1b: 1H NMR (500 MHz, CDCl3): d (ppm) 7.40 (t, JH–H = 7.6 Hz,
3
0
2H), 7.32 (d, 3JH–H = 7.6 Hz, 2H), 7.28 (t, JH–H = 7.4 Hz, 1H), 5.43
3
0
0
(dm, 2JH–F = 56.3 Hz, 1H), 2.7 (m, 4H); 13C NMR (CDCl3): d (ppm)
1
150.1, 129.0, 126.9, 124.3, 85.0 (d, JC–F = 208.3 Hz), 51.7 (d,
3JC–F = 19.2 Hz), 44.1 (d, JC–F = 20.2 Hz); 19F NMR (CDCl3): d
2
(ppm) ꢀ65.8.